Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

InterMune Inc (ITMN), United Therapeutics Corporation (UTHR), Cyberonics Inc. (CYBX): Palo Alto Investors Loves Healthcare Stocks

Palo Alto Investors is a hedge fund founded by William Leland Edwards in 1989, and managed by him ever since. The fund invests in small-cap stocks, with market capitalizations under $3 billion, and typically focuses on healthcare, energy, and technology sectors. In this article, we will take a look at its three largest equity holdings for the second quarter of 2014: InterMune Inc (NASDAQ:ITMN), United Therapeutics Corporation (NASDAQ:UTHR) and Cyberonics, Inc. (NASDAQ:CYBX).

InterMune Inc (NASDAQ:ITMN) is a $7.9 billion market cap biopharmaceutical firm focused on developing therapies for the treatment of lung and fibrotic diseases. Over the second quarter, Palo Alto added 17% to its holdings at the company, and now owns roughly 5.13 million shares, worth more than $226 million. This stake accounts for more than 16.8% of the fund’s equity portfolio’s total value, and makes it the second largest hedge fund shareholder of record, amongst those we track, only outranked by Samuel Isaly’s Orbimed Advisors, which last disclosed ownership of 5.42 million shares of InterMune Inc (NASDAQ:ITMN)’s Common Stock.

InterMune Inc (NASDAQ:ITMN)

People familiar to the matter have been speculating about InterMune Inc (NASDAQ:ITMN) working with Goldman Sachs Group Inc (NYSE:GS) and Centerview Partners LLC to look for potential buyers; needless to say, this could certainly benefit shareholders. Bidders included Roche Holdings Ltd-Spons ADR (PINK:RHHBY), Sanofi SA (ADR) (NYSE:SNY) and GlaxoSmithKline plc (ADR) (NYSE:GSK). However, it was Roche Holdings Ltd-Spons ADR (PINK:RHHBY) that finally won the battle, and declared in late-August a definitive merger agreement for $8.3 billion in cash. Roche offered $74 per share, which represented a 38% premium over InterMune’s closing price on the date of the announcement. The stock is already up 400% year-to-date –so the time to invest has passed already.

Second in line is United Therapeutics Corporation (NASDAQ:UTHR), a $5.3 billion market cap biotechnology company that saw the fund boost its exposure by 11% over the second quarter. Palo Alto now holds 1.21 million shares of Common Stock, worth more than $100 million. This makes it one of the largest hedge fund shareholders, trailed by Joel Greenblatt’s Gotham Asset Management, which owns 646,066 shares.

United Therapeutics Corporation (NASDAQ:UTHR)’s stock had been trading at low prices since the begging of the year, and suddenly skyrocketed on August 28. Why? Well, the company received on that date a favorable legal decision regarding its lead drug, Remodulin, which avoided a generic version from coming out to the market.

Last in this list is Cyberonics, Inc. (NASDAQ:CYBX), a $1.5 billion market cap medical devices company, which also saw a slight increase in Palo Alto’s stake over the second quarter. The fund last declared holding 1.71 million shares. worth more than $100 million. The fund is, once again, the second largest hedge fund shareholder, among those that we track, only surpassed by Jim Simons’ Renaissance Technologies, which owns 2.41 million shares of the company.

Despite this funds’ bullishness, the stock did not deliver good returns this year. Since the beginning of 2014, the stock has plummeted more than 17%, as thousands of deaths and injuries could be linked to Cyberonics, Inc. (NASDAQ:CYBX)’s devices. Several other factors could also impact negatively on the company’s results in the future. Nonetheless, analysts still like the stock, and have fixed a median target price of $70.00 per share, which implies a 29% upside potential.

Disclosure: Javier Hasse holds no positions in any stocks or funds mentioned.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!